As of June 30, 2026, Human Metabolome Technologies, Inc. carries a market capitalization of 3.33B, placing it among publicly traded companies globally. Its enterprise value stands at 1.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.33B |
| Enterprise Value | 1.99B |
Human Metabolome Technologies, Inc.'s next confirmed earnings release is scheduled for February 18, 2027.
| Earnings Date | 2/18/2027 |
As of June 30, 2026, Human Metabolome Technologies, Inc. has 5.42M shares outstanding.
| Shares Outstanding | 5.42M |
These figures are as of June 30, 2026.
| PB Ratio | 1.82 |
| P/TBV Ratio | 1.85 |
As of June 30, 2026, Human Metabolome Technologies, Inc. maintains a current ratio of 4.03, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.03 |
| Quick Ratio | 3.29 |
| Debt / Equity | 5.68 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 62.75 |
As of the close on November 17, 2026, Human Metabolome Technologies, Inc.'s stock has declined approximately 13.60% over the past 52 weeks. The 50-day moving average sits at 597.18, while the 200-day moving average is 642.88.
| 52-Week Price Change | -13.60% |
| 50-Day Moving Average | 597.18 |
| 200-Day Moving Average | 642.88 |
As of June 30, 2026, Human Metabolome Technologies, Inc. holds 1.44B in cash and equivalents against 103.88M in total debt, resulting in a net debt position of -1.34B. Total book value stands at 1.83B, with working capital of 1.33B providing operational flexibility.
| Cash & Cash Equivalents | 1.44B |
| Total Debt | 103.88M |
| Net Debt | -1.34B |
| Equity (Book Value) | 1.83B |
| Book Value Per Share | 337.45 |
| Working Capital | 1.33B |
Already premium?